Dimetacrine

Dimetacrine

SCHEMBL29578094

CN(C)CCCN1c2ccccc2C(C)(C)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 1.00
CYP1A2 P05177 8/20 1.00
KMT2A Q03164 4/20 1.00
SLC6A4 P31645 7/20 0.59
HTR1A P08908 7/20 0.59
LMNA P02545 6/20 0.59
MAPT P10636 6/20 0.59
DRD2 P14416 6/20 0.59
HRH1 P35367 6/20 0.59
HTR2A P28223 5/20 0.59
HTR6 P50406 5/20 0.59
CHRM2 P08172 5/20 0.59
CHRM1 P11229 5/20 0.59
DRD1 P21728 5/20 0.59
SLC6A2 P23975 5/20 0.59
ADRA1A P35348 5/20 0.59
OPRM1 P35372 5/20 0.59
DRD3 P35462 5/20 0.59
MTOR P42345 5/20 0.59
KCNH2 Q12809 5/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimetacrine SCHEMBL50120 1.00 CYP2D6 (1.00) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL11640552 0.88 CYP2D6 (0.78) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
Dimetacrine SCHEMBL3501515 0.87 CYP2D6 (0.75) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
Dimetacrine SCHEMBL3501514 0.87 CYP2D6 (0.75) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL13231573 0.82 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
Dimetacrine SCHEMBL28221926 0.82 HRH1 (0.71) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL17739604 0.81 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL12265301 0.79 CYP2D6 (0.66) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL29025681 0.78 CYP2D6 (0.64) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL11640659 0.78 KMT2A (0.63) CYP2D6CYP1A2KMT2ASLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-119587525-A Dimethocaine composite preparation and preparation method thereof 海南三帝制药有限公司 2025-03-11 CN claimed
EP-3706762-B1 N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO UNIV EMORY (US) 2024-10-16 EP claimed
CN-118541143-A Gastric retentive oral dosage unit containing local anesthetic 欧莱克萨有限公司 2024-08-23 CN claimed
CN-117651571-A Powder preparation for tissue repair, preparation method thereof and injection composition for tissue repair comprising powder preparation 三养控股公司 2024-03-05 CN claimed
CN-117425498-A Novel peptide conjugates 艾缇亚(上海)制药有限公司 2024-01-19 CN claimed
CN-116615261-A Crosslinked hyaluronic acid hydrogel crosslinked using crosslinking agent and polyol and filler comprising same 株式会社LG化学 2023-08-18 CN claimed
EP-4577246-A1 DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE The Johns Hopkins University (US) 2025-07-02 EP disclosed
CN-120129541-A Powder formulation for tissue repair and injection composition for tissue repair comprising the same 三养控股公司 2025-06-10 CN disclosed
CN-119587525-A Dimethocaine composite preparation and preparation method thereof 海南三帝制药有限公司 2025-03-11 CN disclosed
CN-113227131-B Modified antibody Fc and methods of use thereof 豪夫迈·罗氏有限公司 2025-03-04 CN disclosed
CN-113413393-B Multi-unit drug delivery device and method 塔里斯生物医药公司 2025-03-04 CN disclosed
WO-2024044760-A9 DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE THE JOHNS HOPKINS UNIVERSITY (US) 2024-12-26 WO disclosed
CN-116615261-A Crosslinked hyaluronic acid hydrogel crosslinked using crosslinking agent and polyol and filler comprising same 株式会社LG化学 2023-08-18 CN disclosed
CN-109996546-B P2X 3 And/or P2X 2/3 Compounds and methods 阿沙纳生物科学公司 2023-06-27 CN disclosed
CN-116322626-A Methods and compositions for classifying and/or treating postchin retraction in a subject in need thereof 阿勒根公司 2023-06-23 CN disclosed
CN-116075295-A Novel injectable oil-based pharmaceutical compositions 南爱克萨股份公司 2023-05-05 CN disclosed
CN-116056685-A Methods, kits and compositions of novel agarose-based dermal fillers with enhanced rheological properties and safety performance 先进美学科技公司 2023-05-02 CN disclosed
CN-115996686-A Medical device comprising expandable muscle polymer 巴德外周血管股份有限公司 2023-04-21 CN disclosed
US-20220127613-A1 Functionally-Modified Oligonucleotides And Subunits Thereof SAREPTA THERAPEUTICS INC (US) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127613-A1 Functionally-Modified Oligonucleotides And Subunits Thereof RTCB, NSUN3, NSUN2 CYP2D6 4218/4885CYP1A2 4739/4885KMT2A 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.